
- Pharmaceutical Technology\'s In the Lab eNewsletter-07-03-2018
- Volume 13
- Issue 7
Cambrex Adds R&D Lab for Generic APIs
Cambrex expands its generic API research and development capabilities at its Milan, Italy site.
Cambrex Corporation continued its expansion plans with a June 12, 2018 announcement of the construction of a new 150-sq.-meter R&D laboratory at its site in Paullo, Milan, Italy. The company also announced the recruitment of additional scientists to increase the number of generic APIs in the company’s development portfolio.
The laboratory, which will combine chemistry and analytical development capabilities, will include 14 fume hoods, glass-lined reactors, and liquid chromatography and gas chromatography systems. The company reported in a press statement that construction will be completed by the end of 2018, with installation and validation of instruments to take place in the first quarter of 2019.
The Milan site comprises seven production departments, including a pilot plant, kilo-scale plant, and development and analytical laboratories.
Source:
Articles in this issue
over 7 years ago
Dissolution Testing: Keeping It Simpleover 7 years ago
Improvements Needed for Adventitious Agent Testingover 7 years ago
Sciex’s New Mass Spec Technologies Enhance Lab Analyticsover 7 years ago
Alcami Expands Laboratory Services Programover 7 years ago
Shimadzu’s New Q-TOF System Enhances Mass Spectrometryover 7 years ago
Waters’ New UPLC Platform Meets Evolving Chromatography Needsover 7 years ago
Juniper Pharma Services Expands Laboratory FacilitiesNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





